#BEGIN_DRUGCARD DB00730

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Rapidly absorbed and peak plasma concentration is reached within 1 to 2 hours after the oral administration of a suspension. Some systemic absorption may occur from topical preparations applied to the skin.

# Biotransformation:
Hepatic. Metabolized almost completely to the 5-hydroxy form which appears in the urine as glucuronide or sulfate conjugates.

# Brand_Mixtures:
Tresaderm Dermatologic Solution (Dexamethasone + Neomycin sulfate + Thiabendazole)

# Brand_Names:
Apl-Luster
Arbotect
Bioguard
Bovizole
Chemviron TK 100
Cropasal
Drawipas
Eprofil
Equivet TZ
Equizole
Hokustar hp
Hymush
Lombristop
Mertec
Mertect
Mertect 160
Mertect 340f
Mertect lsp
Metasol TK 10
Metasol TK 100
Mintesol
Mintezol
Minzolum
Mycozol
Nemacin
Nemapan
Omnizole
Ormogal
Polival
RPH
Sanaizol 100
Sistesan
Storite
TBZ 6
TBZ 60W
Tebuzate
Tecto
Tecto 10P
Tecto 40F
Tecto 60
Tecto B
Tecto rph
Testo
Thiaben
Thibendole
Thibenzol
Thibenzole
Thibenzole 200
Thibenzole att
Thiprazole
Tiabenda
Tibimix 20
Tobaz
Top form wormer
Triasox
Tubazole

# CAS_Registry_Number:
148-79-8

# ChEBI_ID:
45979

# Chemical_Formula:
C10H7N3S

# Chemical_IUPAC_Name:
2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazole

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
140228

# Description:
2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)

# Dosage_Forms:
Suspension	Oral
Tablet, chewable	Oral

# Drug_Category:
Anthelmintics
Antinematodal Agents

# Drug_Interactions:
Acenocoumarol	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Acenocoumarol by decreasing Acenocoumarol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Acenocoumarol if Thiabendazole is initiated, discontinued or dose changed.
Alosetron	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed.
Aminophylline	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Aminophylline by decreasing Aminophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Aminophylline if Thiabendazole is initiated, discontinued or dose changed.
Betaxolol	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Betaxolol by decreasing Betaxolol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Betaxolol if Thiabendazole is initiated, discontinued or dose changed
Caffeine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Caffeine by decreasing Caffeine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Caffeine if Thiabendazole is initiated, discontinued or dose changed.
Clomipramine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clomipramine by decreasing Clomipramine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clomipramine if Thiabendazole is initiated, discontinued or dose changed.
Clozapine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clozapine by decreasing Clozapine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clozapine if Thiabendazole is initiated, discontinued or dose changed.
Cyclobenzaprine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Cyclobenzaprine by decreasing Cyclobenzaprine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Cyclobenzaprine if Thiabendazole is initiated, discontinued or dose changed.
Dacarbazine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed.
Doxepin	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Doxepin by decreasing Doxepin metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Doxepin if Thiabendazole is initiated, discontinued or dose changed.
Duloxetine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Duloxetine if Thiabendazole is initiated, discontinued or dose changed.
Flutamide	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Flutamide by decreasing Flutamide metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Flutamide if Thiabendazole is initiated, discontinued or dose changed.
Fluvoxamine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Fluvoxamine if Thiabendazole is initiated, discontinued or dose changed.
Guanabenz	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Guanabenz by decreasing Guanabenz metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Guanabenz if Thiabendazole is initiated, discontinued or dose changed.
Oxtriphylline	Thiabendazole increases the effect and toxicity of theophylline
Ramelteon	Thiabendazole increases levels/toxicity of ramelteon
Tacrine	The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Thiabendazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Thiabendazole is initiated, discontinued or if the dose is changed.
Theophylline	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Theophylline by decreasing Theophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Theophylline if Thiabendazole is initiated, discontinued or dose changed.
Thiothixene	The strong CYP1A2 inhibitor, Thiobendazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Thiobendazole is initiated, discontinued or dose changed.
Tizanidine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Tizanidine by decreasing Tizanidine metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Tizanidine if Thiabendazole is initiated, discontinued or dose changed.
Trifluoperazine	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Trifluoperazine by decreasing Trifluoperazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Trifluoperazine if Thiabendazole is initiated, discontinued or dose changed.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.47

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
50 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Thiabendazole

# HET_ID:
TMG

# Half_Life:
The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours).

# InChI_Identifier:
InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)

# InChI_Key:
InChIKey=WJCNZQLZVWNLKY-UHFFFAOYSA-N

# Indication:
For the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00372

# LIMS_Drug_ID:
730

# Mechanism_Of_Action:
The precise mode of action of thiabendazole on the parasite is unknown, but it most likely inhibits the helminth-specific enzyme fumarate reductase.

# Melting_Point:
300 °C

# Molecular_Weight_Avg:
201.248

# Molecular_Weight_Mono:
201.036067929

# Organisms_Affected:
Roundworms, hookworms, and other helminth species

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164746466

# Pharmacology:
Thiabendazole is a fungicide and parasiticide. Thiabendazole is also a chelating agent, which means that it is used medicinally to bind metals in cases of metal poisoning, such as lead poisoning, mercury poisoning or antimony poisoning. Thiabendazole is vermicidal and/or vermifugal against <i>Ascaris lumbricoides</i> ("common roundworm"), <i>Strongyloides stercoralis</i> (threadworm), <i>Necator americanus</i>, <i>Ancylostoma duodenale</i> (hookworm), <i>Trichuris trichiura</i> (whipworm), <i>Ancylostoma braziliense</i> (dog and cat hookworm), <i>Toxocara canis</i>, <i>Toxocara cati</i> (ascarids), and <i>Enterobius vermicularis</i> (pinworm). Thiabendazole also suppresses egg and/or larval production and may inhibit the subsequent development of those eggs or larvae which are passed in the feces.

# Predicted_LogP_Hydrophobicity:
2.47

# Predicted_LogS:
-3.2

# Predicted_Water_Solubility:
1.38e-01 g/l

# Primary_Accession_No:
DB00730

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5430

# PubChem_Substance_ID:
46505131

# RxList_Link:
http://www.rxlist.com/cgi/generic2/thiabendazole.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01252
DB08630

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N1C2=CC=CC=C2N=C1C1=CSC=N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
2-(1,3-Thiazol-4-yl)-1H-benzimidazole
TBDZ
Thiabendazol
Thiabendole
Thiabenzazole
Thiabenzole
Tiabendazol
Tiabendazole

# Synthesis_Reference:
Not Available

# Toxicity:
Overdosage may be associated with transient disturbances of vision and psychic alterations. The oral LD 50 is 3.6 g/kg, 3.1 g/kg and 3.8 g/kg in the mouse, rat, and rabbit respectively.

# Update_Date:
2013-02-08 16:19:35 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Thiabendazole

# pKa_Isoelectric_Point:
4.64 (at 25 °C)

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_1_ID:
4200

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP1A1

# Phase_1_Metabolizing_Enzyme_2_ID:
6024

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 1A1

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P04798

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11031122	Ge Z, Feng Y, Dangler CA, Xu S, Taylor NS, Fox JG: Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
J01611

# Drug_Target_1_GenBank_ID_Protein:
145263

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
frdA

# Drug_Target_1_Gene_Sequence:
>1809 bp
GTGCAAACCTTTCAAGCCGATCTTGCCATTGTAGGCGCCGGTGGCGCGGGATTACGTGCT
GCAATTGCTGCCGCGCAGGCAAATCCGAATGCAAAAATCGCACTAATCTCAAAAGTATAC
CCGATGCGTAGCCATACCGTTGCTGCAGAAGGGGGCTCCGCCGCTGTCGCGCAGGATCAT
GACAGCTTCGAATATCACTTTCACGATACAGTAGCGGGTGGCGACTGGTTGTGTGAGCAG
GATGTCGTGGATTATTTCGTCCACCACTGCCCAACCGAAATGACCCAACTGGAACTGTGG
GGATGCCCATGGAGCCGTCGCCCGGATGGTAGCGTCAACGTACGTCGCTTCGGCGGCATG
AAAATCGAGCGCACCTGGTTCGCCGCCGATAAGACCGGCTTCCATATGCTGCACACGCTG
TTCCAGACCTCTCTGCAATTCCCGCAGATCCAGCGTTTTGACGAACATTTCGTGCTGGAT
ATTCTGGTTGATGATGGTCATGTTCGCGGCCTGGTAGCAATGAACATGATGGAAGGCACG
CTGGTGCAGATCCGTGCTAACGCGGTCGTTATGGCTACTGGCGGTGCGGGTCGCGTTTAT
CGTTACAACACCAACGGCGGCATCGTTACCGGTGACGGTATGGGTATGGCGCTAAGCCAC
GGCGTTCCGCTGCGTGACATGGAATTCGTTCAGTATCACCCAACCGGTCTGCCAGGTTCC
GGTATCCTGATGACCGAAGGTTGCCGCGGTGAAGGCGGTATTCTGGTCAACAAAAATGGC
TACCGTTATCTGCAAGATTACGGCATGGGCCCGGAAACTCCGCTGGGCGAGCCGAAAAAC
AAATATATGGAACTGGGTCCACGCGACAAAGTCTCTCAGGCCTTCTGGCACGAATGGCGT
AAAGGCAACACCATCTCCACGCCGCGTGGCGATGTGGTTTATCTCGACTTGCGTCACCTC
GGCGAGAAAAAACTGCATGAACGTCTGCCGTTCATCTGCGAACTGGCGAAAGCGTACGTT
GGCGTCGATCCGGTTAAAGAACCGATTCCGGTACGTCCGACCGCACACTACACCATGGGC
GGTATCGAAACCGATCAGAACTGTGAAACCCGCATTAAAGGTCTGTTCGCCGTGGGTGAA
TGTTCCTCTGTTGGTCCGCACGGTGCAAACCGTCTGGGTTCTAACTCCCTGGCGGAACTG
GTGGTCTTCGGCCGTCTGGCCGGTGAACAAGCGACAGAGCGTGCAGCAACTGCCGGTAAT
GGCAACGAAGCGGCAATTGAAGCGCAGGCAGCTGGCGTTGAACAACGTCTGAAAGATCTG
GTTAACCAGGATGGCGGCGAAAACTGGGCGAAGATCCGCGACGAAATGGGCCTGGCTATG
GAAGAAGGCTGCGGTATCTACCGTACGCCGGAACTGATGCAGAAAACCATCGACAAGCTG
GCAGAGCTGCAGGAACGCTTCAAGCGCGTGCGCATCACCGACACTTCCAGCGTGTTCAAC
ACCGACCTGCTCTACACCATTGAACTGGGCCACGGTCTGAACGTTGCTGAATGTATGGCG
CACTCCGCAATGGCACGTAAAGAGTCCCGCGGCGCGCACCAGCGTCTGGACGAAGGTTGC
ACCGAGCGTGACGACGTCAACTTCCTCAAACACACCCTCGCCTTCCGCGATGCTGATGGC
ACGACTCGCCTGGAGTACAGCGACGTGAAGATTACTACGCTGCCGCCAGCTAAACGCGTT
TACGGTGGCGAAGCGGATGCAGCCGATAAGGCGGAAGCAGCCAATAAGAAGGAGAAGGCG
AATGGCTGA

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
10373108	Iverson TM, Luna-Chavez C, Cecchini G, Rees DC: Structure of the Escherichia coli fumarate reductase respiratory complex. Science. 1999 Jun 18;284(5422):1961-6.
10535936	Yi X, Mroczko M, Manoj KM, Wang X, Hager LP: Replacement of the proximal heme thiolate ligand in chloroperoxidase with a histidine residue. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12412-7.
11850430	Iverson TM, Luna-Chavez C, Croal LR, Cecchini G, Rees DC: Crystallographic studies of the Escherichia coli quinol-fumarate reductase with inhibitors bound to the quinol-binding site. J Biol Chem. 2002 May 3;277(18):16124-30. Epub 2002 Feb 15.
1856194	Schroder I, Gunsalus RP, Ackrell BA, Cochran B, Cecchini G: Identification of active site residues of Escherichia coli fumarate reductase by site-directed mutagenesis. J Biol Chem. 1991 Jul 25;266(21):13572-9.
2668268	Blaut M, Whittaker K, Valdovinos A, Ackrell BA, Gunsalus RP, Cecchini G: Fumarate reductase mutants of Escherichia coli that lack covalently bound flavin. J Biol Chem. 1989 Aug 15;264(23):13599-604.
7037404	Cole ST: Nucleotide sequence coding for the flavoprotein subunit of the fumarate reductase of Escherichia coli. Eur J Biochem. 1982 Mar 1;122(3):479-84.
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
605

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
65841

# Drug_Target_1_Name:
Fumarate reductase flavoprotein subunit

# Drug_Target_1_Number_of_Residues:
601

# Drug_Target_1_PDB_ID:
1L0V

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00890	FAD_binding_2
PF02910	Succ_DH_flav_C

# Drug_Target_1_Protein_Sequence:
>Fumarate reductase flavoprotein subunit
QTFQADLAIVGAGGAGLRAAIAAAQANPNAKIALISKVYPMRSHTVAAEGGSAAVAQDHD
SFEYHFHDTVAGGDWLCEQDVVDYFVHHCPTEMTQLELWGCPWSRRPDGSVNVRRFGGMK
IERTWFAADKTGFHMLHTLFQTSLQFPQIQRFDEHFVLDILVDDGHVRGLVAMNMMEGTL
VQIRANAVVMATGGAGRVYRYNTNGGIVTGDGMGMALSHGVPLRDMEFVQYHPTGLPGSG
ILMTEGCRGEGGILVNKNGYRYLQDYGMGPETPLGEPKNKYMELGPRDKVSQAFWHEWRK
GNTISTPRGDVVYLDLRHLGEKKLHERLPFICELAKAYVGVDPVKEPIPVRPTAHYTMGG
IETDQNCETRIKGLFAVGECSSVGLHGANRLGSNSLAELVVFGRLAGEQATERAATAGNG
NEAAIEAQAAGVEQRLKDLVNQDGGENWAKIRDEMGLAMEEGCGIYRTPELMQKTIDKLA
ELQERFKRVRITDTSSVFNTDLLYTIELGHGLNVAECMAHSAMARKESRGAHQRLDEGCT
ERDDVNFLKHTLAFRDADGTTRLEYSDVKITTLPPAKRVYGGEADAADKAEAANKKEKAN
G

# Drug_Target_1_Reaction:
succinate + acceptor = fumarate + reduced acceptor

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Two distinct, membrane-bound, FAD-containing enzymes are responsible for the catalysis of fumarate and succinate interconversion; the fumarate reductase is used in anaerobic growth, and the succinate dehydrogenase is used in aerobic growth

# Drug_Target_1_SwissProt_ID:
P00363

# Drug_Target_1_SwissProt_Name:
FRDA_ECOLI

# Drug_Target_1_Synonyms:
EC 1.3.99.1

# Drug_Target_1_Theoretical_pI:
6.24

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00730
